Aetna Cancer Pathways Program Aims For 'Value-Based' Prescribing
This article was originally published in The Pink Sheet Daily
“For many malignancies, there is no ‘best treatment’ but there may be tremendous differences in cost,” Aetna National Medical Director, Oncology Solutions Michael Kolodziej says.
You may also be interested in...
The bundled payment pilot program resulted in a 34% decrease in overall cancer treatment costs among participating medical centers despite a 179% increase in drug spending, according to results released July 8.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.